VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Molecular agents targeting the epidermal growth factor receptor (EGFR)‐, anaplastic lymphoma kinase (ALK)‐ or c‐ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Watanabe, Hiromi, Ichihara, Eiki, Kayatani, Hiroe, Makimoto, Go, Ninomiya, Kiichiro, Nishii, Kazuya, Higo, Hisao, Ando, Chihiro, Okawa, Sachi, Nakasuka, Takamasa, Kano, Hirohisa, Hara, Naofumi, Hirabae, Atsuko, Kato, Yuka, Ninomiya, Takashi, Kubo, Toshio, Rai, Kammei, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088971/
https://ncbi.nlm.nih.gov/pubmed/33410241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14801
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak